The Comorbidity of Lung Cancer and ILD: A Review

Abstract

Patients with interstitial lung disease (ILD) and especially with idiopathic pulmonary fibrosis(IPF) suffer from reduced survival expectation and risk of exacerbations. Lung cancer is a relevant comorbidity in ILD patients and associated with impaired survival.

The most frequent ILD among patients with NSCLC (Non-small cell lung cancer) is idiopathic pulmonary fibrosis (IPF), which is associated with an greater decline in lung function and a higher risk of death.

The prevalence of lung cancer in patients with ILD is up to 10% and in autopsy studies a prevalence up to 48% has been found.

There are no guidelines for patients with lung cancer and ILD. Moreover, no adequate evidence is available.

Therefore, we reviewed currently available literature to present an overview of the state of the art.

In this review we focus on staging and treatment of the comorbidity of lung cancer and ILD.

Zusammenfassung

Patienten mit interstitieller Lungenerkrankung (ILD) und insbesondere mit idiopathischer Lungenfibrose (IPF) leiden unter einer verringerten Lebenserwartung und einem erhöhten Risiko für Exazerbationen. Lungenkrebs ist eine relevante Komorbidität bei ILD-Patienten und mit einer verschlechterten Überlebensprognose verbunden. Die häufigste ILD bei Patienten mit NSCLC (Nicht-kleinzelligem Lungenkrebs) ist die idiopathische Lungenfibrose (IPF), die mit einem beschleunigten Rückgang der Lungenfunktion und einem höheren Sterberisiko einhergeht. Die Prävalenz von Lungenkrebs bei Patienten mit ILD liegt bei bis zu 10% und in Autopsiestudien wurde eine Prävalenz von bis zu 48% festgestellt. Es gibt keine Richtlinien für Patienten mit Lungenkrebs und ILD, zudem fehlt es an ausreichender Evidenz. Daher haben wir die Literatur überprüft, um einen Überblick über den aktuellen Stand der Wissenschaft zu geben. In dieser Übersicht konzentrieren wir uns auf die Diagnostik und Behandlung der Komorbidität Lungenkrebs und ILD.

Keywords

ILD - IPF - lung cancer and ILD - antifibrotic treatment - ?

Schlüsselwörter

ILD - IPF - Lungenkrebs und ILD - antifibrotische Therapie - ökologische Therapie bei NSCLC und ILD

Publication History

Received: 15 December 2024

Accepted: 03 January 2025

Article published online:
22 January 2025

• References

• 1 Margaritopoulos GA, Antoniou KM, Wells AU. Comorbidities in interstitial lung diseases. Eur Respir Rev 2017; 26: 160027
• 2 Ikeda S, Kato T, Kenmotsu H. et al. Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia. Cancers (Basel) 2021; 13: 3979
• 3 Mei Q, Liu Z, Zuo H. et al. Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis. Front Pharmacol 2021; 12: 797292
• 4 Abu Qubo A, Numan J, Snijder J. et al. Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges. Breathe 2023; 18: 220147
• 5 Matsushita H, Tanaka S, Saiki Y. et al. Lung cancer associated with usual interstitial pneumonia. Pathol Int 1995; 45: 925-932
• 6 Vancheri C. Idiopathic pulmonary fibrosis and cancer: do they really look similar?. BMC Med 2015; 13: 220
• 7 Ballester B, Milara J, Cortijo J. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets. Int J Mol Sci 2019; 20: 593
• 8 Herbst RS, Garon EB, Kim D-W. et al. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. J Thorac Oncol 2021; 16: 1718-1732
• 9 Frank AJ, Dagogo-Jack I, Dobre IA. et al. Management of Lung Cancer in the Patient with Interstitial Lung Disease. Oncologist 2023; 28: 12-22
• 10 Reck M, Rodriguez-Abreu D, Robinson AG. et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50. J Clin Oncol 2021; 39: 2339-2349
• 11 Mollica C, Paone G, Conti V. et al. Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. Respiration 2010; 79: 209-215
• 12 Schrader M, Sathananthan M, Jeganathan N. Patients With Idiopathic Pulmonary Fibrosis Admitted to the ICU With Acute Respiratory Failure – A Reevaluation of the Risk Factors and Outcomes. J Intensive Care Med 2022; 37: 342-351
• 13 Finnerty JP, Ponnuswamy A, Dutta P. et al. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med 2021; 21: 411
• 14 Wells AU, Flaherty KR, Brown KK. et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases – subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; 8: 453-460
• 15 Yamaguchi T, Shimizu J, Shigematsu F. et al. Atezolizumab and nintedanib in patients with non-small cell lung cancer and interstitial lung disease. J Thorac Dis 2024; 16: 3371-3380
• 16 Naoi H, Suzuki Y, Mori K. et al. Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis. Thorax 2022; 77: 727-730
• 17 Lee SH, Sung C, Lee HS. et al. Is 18F-FDG PET/CT useful for the differential diagnosis of solitary pulmonary nodules in patients with idiopathic pulmonary fibrosis?. Ann Nucl Med 2018; 32: 492-498
• 18 Baughman RP, Valeyre D, Korsten P. et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021; 58: 2004079
• 19 Amundson WH, Racila E, Allen T. et al. Acute exacerbation of interstitial lung disease after procedures. Respir Med 2019; 150: 30-37
• 20 Guerrera F, Costardi L, Rosboch GL. et al. Awake or intubated surgery in diagnosis of interstitial lung diseases? A prospective study. ERJ Open Res 2021; 7: 00630-02020
• 21 Fujita T, Hiroishi T, Shikano K. et al. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias. Intern Med 2018; 57: 1827-1832
• 22 Kenmotsu H, Yoh K, Mori K. et al. Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease. Cancer Sci 2019; 110: 3738-3745
• 23 Pérol M, Felip E, Dafni U. et al. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Ann Oncol 2022; 33: 511-521
• 24 Axtell AL, David EA, Block MI. et al. Association Between Interstitial Lung Disease and Outcomes After Lung Cancer Resection. Ann Thorac Surg 2023; 116: 533-541
• 25 Otsubo K, Kishimoto J, Ando M. et al. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. Eur Respir J 2022; 60: 2200380
• 26 Ikeda S, Ogura T, Kato T. et al. Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc 2024; 21: 635-643